SCHEMBL10969744

SCHEMBL10969744

COc1ccc(C(=O)c2cccc(C(=O)c3ccc(OC)cc3)c2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.68
GAA P10253 1/20 0.68
STS P08842 3/20 0.67
KMT2A Q03164 2/20 0.63
MEN1 O00255 1/20 0.63
LMNA P02545 1/20 0.63
MAPT P10636 1/20 0.63
MAPK1 P28482 1/20 0.63
RAB9A P51151 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
RXFP1 Q9HBX9 1/20 0.63
HPGD P15428 1/20 0.63
CTSL P07711 1/20 0.61
TUBB4A P04350 1/20 0.61
TUBB P07437 1/20 0.61
TUBA3C P0DPH7 1/20 0.61
TUBA1B P68363 1/20 0.61
TUBA4A P68366 1/20 0.61
TUBB4B P68371 1/20 0.61
TUBB3 Q13509 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27399132 0.94 ALDH1A1 (0.62) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL15264157 0.93 CTSK (0.64) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL12276577 0.93 STS (0.60) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL8811453 0.93 CA1 (0.63) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL2303699 0.92 STS (0.72) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL12857682 0.91 KCNK3 (0.61) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL9854021 0.91 HPGD (0.59) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL17285814 0.90 SRD5A2 (0.62) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL15372973 0.90 STS (0.57) ALDH1A1GAASTSKMT2AMEN1
SCHEMBL12362759 0.90 TUBB4A (0.72) ALDH1A1GAAKMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12017972-B2 All-aromatic liquid-crystalline homo-polyimides with aromatic endgroups and crosslinked products therefrom THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2024-06-25 US disclosed
US-12017972-B2 All-aromatic liquid-crystalline homo-polyimides with aromatic endgroups and crosslinked products therefrom THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE AIR FORCE (US) 2024-06-25 US disclosed
EP-2828241-B1 COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS MATEON THERAPEUTICS INC (US) 2018-09-12 EP disclosed
US-9873668-B2 Compositions and methods for inhibition of cathepsins MATEON THERAPEUTICS, INC. (US) 2018-01-23 US disclosed
US-9873668-B2 Compositions and methods for inhibition of cathepsins MATEON THERAPEUTICS, INC. (US) 2018-01-23 US disclosed
US-20160368869-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS BAYLOR UNIVERSITY 2016-12-22 US disclosed
US-20160368869-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS BAYLOR UNIVERSITY 2016-12-22 US disclosed
US-9458103-B2 Compositions and methods for inhibition of cathepsins MATEON THERAPEUTICS, INC. (US) 2016-10-04 US disclosed
US-9458103-B2 Compositions and methods for inhibition of cathepsins MATEON THERAPEUTICS, INC. (US) 2016-10-04 US disclosed
US-20150031915-A1 Compositions and Methods for Inhibition of Cathepsins MATEON THERAPEUTICS, INC. 2015-01-29 US disclosed
US-20150031915-A1 Compositions and Methods for Inhibition of Cathepsins MATEON THERAPEUTICS, INC. 2015-01-29 US disclosed
US-8877967-B2 Compositions and methods for inhibition of cathepsins OXIGENE, INC. (US) 2014-11-04 US disclosed
US-8877967-B2 Compositions and methods for inhibition of cathepsins OXIGENE, INC. (US) 2014-11-04 US disclosed
US-20130296605-A1 Compositions and Methods for Inhibition of Cathepsins MATEON THERAPEUTICS, INC. 2013-11-07 US disclosed
US-20130296605-A1 Compositions and Methods for Inhibition of Cathepsins MATEON THERAPEUTICS, INC. 2013-11-07 US disclosed
WO-2013142038-A2 COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS OXIGENE, INC. (US) 2013-09-26 WO disclosed
EP-0145834-A1 Ion-selective compositions containing certain crown ethers EASTMAN KODAK COMPANY (a New Jersey corporation) (US) 1985-06-26 EP disclosed
US-4504368-A ELECTRODES, CROWN ETHER EASTMAN KODAK COMPANY (US) 1985-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031915-A1 Compositions and Methods for Inhibition of Cathepsins CTSF, CTSS, CTSZ ALDH1A1 2276/4885GAA 17/4885STS 984/4885
US-20130296605-A1 Compositions and Methods for Inhibition of Cathepsins CTSF, CTSS, CTSZ ALDH1A1 2276/4885GAA 17/4885STS 984/4885
US-20160368869-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF CATHEPSINS CTSF, CTSS, CTSZ ALDH1A1 2276/4885GAA 17/4885STS 984/4885
US-12017972-B2 All-aromatic liquid-crystalline homo-polyimides with aromatic endgroups and crosslinked products therefrom TPR, AS3MT, ASF1A ALDH1A1 2790/4885GAA 2119/4885STS 2647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.